| Project description |
| Response to treatment for acute myeloid leukemia (AML) is highly variable due to intrinsic patient-to-patient differences, therefore better understanding of disease biology is essential to improve therapeutic strategies. Changes in the AML genome can alter cellular metabolism, which is important for disease development and can sensitise AML cells to drugs targeting metabolism. However, metabolic dependencies in AML patients have not been extensively studied. The MEET-AML project will investigate metabolic vulnerabilities in AML and integrate the results with DNA, RNA, protein and drug response level data, along with patient social and clinical information. Based on these data, we will develop novel algorithms to identify AML cell dependencies and new therapeutic interventions. In addition, the data will be used to train disease modelling algorithms to inform clinicians about the efficacy and benefit of different therapeutic options, and will also include the patient's perspective. |